FINWIRES · TerminalLIVE
FINWIRES

Alphamab Says Phase 3 Study of Breast Cancer Drug Meets Primary Endpoint

By

Alphamab Oncology (HKG:9966) said a Phase 3 study of Anbenitamab, or KN026, which it co-developed with Shanghai JMT-Bio Technology, a subsidiary of CSPC Pharma (HKG:1093), met its primary endpoint in the first-line treatment of HER2-positive advanced breast cancer, according to a Wednesday bourse filing.

The company said KN026, in combination with albumin-bound docetaxel HB1801, significantly improved progression-free survival and reduced the risk of disease progression or death compared with the current standard regimen of trastuzumab, pertuzumab, and docetaxel.

The study enrolled about 880 patients and compared KN026 plus HB1801 against the standard treatment regimen in patients with HER2-positive advanced breast cancer.

Related Articles

Asia

Virgin Australia Launches Flight Search Functionality in ChatGPT

Virgin Australia Holdings (ASX:VGN) launched flight search functionality within the ChatGPT artificial intelligence chatbot, becoming the first airline in Australia to do so, the company said Wednesday.When prompted with travel needs, ChatGPT will direct customers to Virgin Australia flights and Velocity Frequent Flyer Reward Seat options, eliminating the need to navigate multiple website pages, the company said.The launch builds on a collaboration Virgin Australia entered with ChatGPT developer OpenAI in November 2025.

$ASX:VGN
Asia

Posco Holdings Reports One Death in Shinansan Line Accident

Posco Holdings (KRX:005490) disclosed a serious industrial accident at its Shinansan Line l, which left one worker dead, according to a Wednesday filing with the Korea Exchange.The worker fell from a height during electrical work preparation in a vertical shaft on Tuesday. The cause of the fall hasn't been identified yet, the filing said.Police and the Ministry of Employment and Labor are investigating the incident, and accident prevention measures are being written to prevent a recurrence, it said.

$KRX:005490
Asia

BOE Technology Controlling Unit to Withdraw Beijing Listing Application; Shares Fall 8%

BOE Technology (SHE:000725) controlling subsidiary Energy Technology plans to terminate its application for a public issuance of shares and listing on the Beijing Stock ExchangeEnergy Technology cited adjustments to its development strategy and actual operational needs for the move, according to a Wednesday filing with the Shenzhen bourse.The withdrawal is subject to the approval of the subsidiary's shareholders.Shares of the electronics components producer were down nearly 8% in recent trade.

$SHE:000725